Latest Headlines

1. Salipro Biotech And Daewoong Pharmaceutical Announce Collaboration Agreement To Advance Development Of Novel Therapeutics 6/12/2025

   Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters).

2. Silicogenix Partners With BioDuro To Accelerate Novel Drug Discovery For Complex Diseases 6/10/2025

   Today, Silicogenix (SGX), the pioneer of fit-for-purpose small molecule design technology that empowers polypharmacology and non-traditional drug development, announced a groundbreaking partnership with BioDuro, a trusted global Contract Research, Development, and Manufacturing Organization (CRDMO).

3. China's Center For Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application For Marketing Authorization Of Pimicotinib For Treatment Of Tenosynovial Giant Cell Tumor 6/10/2025

   Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment.

4. Emulate Launches AVA Emulation System To Accelerate Drug Development With First-Of-Its-Kind High-Throughput Organ-Chip Platform 6/10/2025

   Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run.

5. AlphaMeld Corporation And VedTechBio Forge Strategic AI-Powered Drug Discovery Alliance To Transform Metabolic And Liver Disease Therapeutics 6/10/2025

   AlphaMeld Corporation, a global frontrunner in AI-powered drug discovery, and VedTechBio Research Pvt. Ltd., an emerging biopharma technology innovator specializing in translational research and program execution, today announced a multi-program strategic partnership to accelerate the development of novel therapies for metabolic and liver diseases, including obesity and rare hepatic disorders.

6. CN Bio Introduces Cross-Species DILI Services To Enhance In Vitro To In Vivo Extrapolation During Preclinical Drug Development 6/10/2025

   CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal microphysiological system (MPS) models that enhance translatability in preclinical drug safety and toxicology assessments to its Contract Research Services (CRS).

7. Bexorg Announces Research Collaboration With Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform To Enhance CNS Drug Development 6/10/2025

   Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, today announced a multi-program research collaboration with Biohaven Ltd. (NYSE: BHVN) to identify, de-risk, and advance next-generation therapies for CNS disorders.

8. IonQ Speeds Quantum-Accelerated Drug Development Application With AstraZeneca, AWS, And NVIDIA 6/9/2025

   IonQ, a leading commercial quantum computing and networking company, announced results of a collaborative research program between IonQ, AstraZeneca, Amazon Web Services (AWS), and NVIDIA to develop and demonstrate a quantum-accelerated computational chemistry workflow which has the potential to power world-changing innovation in healthcare, life sciences, chemistry, and more.

9. MIT Releases Breakthrough Protein-Binding Affinity Model, Expanding Role Of AI In Drug Discovery 6/6/2025

   Understanding how molecules interact is central to biology: from decoding how living organisms function to uncovering disease mechanisms and developing life-saving drugs. In recent years, models like AlphaFold changed our ability to predict the 3D structure of proteins, offering crucial insights into molecular shape and interaction.

10. Juvenescence Acquires AI Drug Discovery Company Ro5 To Boost R&D Capabilities And Drive Pipeline Of Medicines To Extend Healthy Lifespan 6/5/2025

    Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce the acquisition of Ro5 Inc., a proprietary AI drug discovery company.